

Xavier Jais

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4361203/xavier-jais-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142
papers

11,715
citations

53
h-index

107
g-index

151
ext. papers

14,515
ext. citations

7.7
avg. IF

5.67
L-index

#	Paper	IF	Citations
142	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.. <i>Pulmonary Circulation</i> , 2022 , 12, e12023	2.7	
141	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. <i>Frontiers in Medicine</i> , 2022 , 9, 851935	4.9	0
140	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience.. <i>Annals of Cardiothoracic Surgery</i> , 2022 , 11, 143-150	4.7	1
139	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	70
138	Screening for pulmonary arterial hypertension in adults carrying a mutation. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	11
137	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
136	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	22
135	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 842-854	10.2	13
134	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	1
133	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021 , 41, 1549-1562	5.7	2
132	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, 1532-1542.e5	1.5	3
131	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	3
130	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , 2021 , 159, 1197-1207	5.3	5
129	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pi�e de R�sistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 524-525	10.2	0
128	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	
127	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021 , 21, 3388-3400	8.7	2
126	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1306-1315	4.7	0

125	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211030170.	2.7	1
124	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	6
123	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, e90-e91	10.2	
122	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 843-852	10.2	4
121	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	11
120	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	11
119	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020 , 73, 130-139	13.4	28
118	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. <i>International Journal of Clinical Pharmacy</i> , 2020 , 42, 1128-1138	2.3	0
117	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 578-585	0.7	6
116	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	16
115	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2020 , 125, e466-e468	5.4	1
114	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	57
113	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 833-842	5.8	32
112	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019 , 28,	9.8	21
111	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	263
110	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , 2018 , 95, 244-250	3.7	7
109	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018 , 196, 157-164	2.9	22
108	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 647-655	5.8	31

107	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018 , 137, 693-704	16.7	92
106	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. <i>Chest</i> , 2018 , 153, 143-151	5.3	35
105	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 882-892	5.3	7
104	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 1102-1110	5.8	15
103	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 790-794	2.3	3
102	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	37
101	Pulmonary hypertension associated with neurofibromatosis type 1. <i>European Respiratory Review</i> , 2018 , 27,	9.8	18
100	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018 , 13, e0197112	3.7	24
99	Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , 2018 , 13, e0198198	3.7	16
98	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 872-881	5.3	22
97	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 125-134	35.1	76
96	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. <i>Archives of Cardiovascular Diseases</i> , 2017 , 110, 303-316	2.7	31
95	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 404-411	2.7	15
94	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 1234-1242	5.8	25
93	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017 , 65, 1683-1692	11.2	40
92	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 785-794	35.1	133
91	Are indexed values better for defining exercise pulmonary hypertension?. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	2
90	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	62

89	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	298
88	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017 , 26,	9.8	28
87	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. <i>Journal of Cardiac Failure</i> , 2017 , 23, 29-35	3.3	14
86	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 386-398	5.8	12
85	Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2016 , 13 Suppl 3, S248-54	4.7	11
84	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , 2016 , 47, 1436-44	13.6	31
83	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016 , 149, 353-361	5.3	46
82	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. <i>Circulation</i> , 2016 , 133, 859-71	16.7	331
81	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. <i>European Respiratory Review</i> , 2016 , 25, 93-6	9.8	6
80	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , 2016 , 39, 287-94	5.1	26
79	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 541-52	13.6	63
78	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosentan in pULmonary arterial hypeRtEnSion. <i>International Journal of Cardiology</i> , 2016 , 202, 52-8	3.2	25
77	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016 , 150, 256-8	5.3	11
76	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016 , 133, e592-3	16.7	4
75	BMP2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 1668-1681	13.6	49
74	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016 , 48, 1517-1519	13.6	36
73	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016 , 47, 1518-34	13.6	134
72	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 1727-36	13.6	85

71	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 647-56	5.8	6
70	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. <i>European Respiratory Journal</i> , 2016 , 48, 254-7	13.6	17
69	Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 260-8	2.7	19
68	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1469-76	3.8	5
67	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2015 , 184, 763-765	3.2	1
66	Atypical vasculitis mimicking chronic thromboembolic pulmonary hypertension. <i>American Journal of Medicine</i> , 2015 , 128, e47-9	2.4	4
65	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , 2015 , 132, 834-47	16.7	80
64	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015 , 46, 728-31	3.6	154
63	New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2113-31	4	17
62	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015 , 46, 1721-31	13.6	55
61	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 13-26	4	19
60	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. <i>Chest</i> , 2015 , 147, 1385-1394	5.3	26
59	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015 , 94, e1800	1.8	32
58	Chronic thromboembolic pulmonary hypertension. <i>Presse Medicale</i> , 2015 , 44, e409-16	2.2	15
57	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". <i>Circulation</i> , 2015 , 132, e154	16.7	3
56	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , 2015 , 185, 356-71	5.8	116
55	Targeted therapies in pulmonary arterial hypertension. <i>Pharmacology & Therapeutics</i> , 2014 , 141, 172-91	13.9	128
54	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , 2014 , 172, 561-7	3.2	24

53	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2014 , 8, 84-92	4.9	7
52	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. <i>European Respiratory Journal</i> , 2014 , 44, 1069-72	13.6	33
51	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014 , 43, 1691-7	13.6	214
50	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <i>Circulation</i> , 2014 , 130, 2189-208	16.7	209
49	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014 , 44, 1275-88	13.6	135
48	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014 , 44, 1627-34	13.6	66
47	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. <i>European Respiratory Review</i> , 2014 , 23, 260-3	9.8	2
46	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 97	4.2	168
45	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013 , 41, 96-103	13.6	75
44	Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. <i>Respiration</i> , 2013 , 85, 471-7	3.7	19
43	Birth control and pregnancy management in pulmonary hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013 , 34, 681-8	3.9	27
42	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013 , 41, 1302-7	13.6	92
41	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. <i>Chest</i> , 2013 , 144, 1512-1520	5.3	18
40	Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. <i>Annals of Thoracic Surgery</i> , 2012 , 94, 817-24	2.7	93
39	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 150-8	5.8	73
38	Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation</i> , 2012 , 125, 2128-37	16.7	448
37	Pulmonary hypertension in lymphangiomyomatosis: characteristics in 20 patients. <i>European Respiratory Journal</i> , 2012 , 40, 630-40	13.6	58
36	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2012 , 40, 881-5	13.6	161

35	Pulmonary hypertension associated with benfluorex exposure. <i>European Respiratory Journal</i> , 2012 , 40, 1164-72	13.6	60
34	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2012 , 40, 75-83	13.6	39
33	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. <i>European Respiratory Journal</i> , 2012 , 39, 1549-50	13.6	9
32	Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. <i>Circulation</i> , 2012 , 125, 2045-7	16.7	5
31	Pulmonary veno-occlusive disease: the blue noire of pulmonary hypertension in connective tissue diseases?. <i>Presse Medicale</i> , 2011 , 40, e65-78	2.2	21
30	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1585-96	4	19
29	Pulmonary hypertension in patients with neurofibromatosis type I. <i>Medicine (United States)</i> , 2011 , 90, 201-211	1.8	42
28	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011 , 8, 526-38	14.8	102
27	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. <i>Circulation</i> , 2011 , 124, 1973-81	16.7	630
26	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2010 , 31, 1898-907	9.5	139
25	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 851-61	10.2	209
24	Pulmonary veno-occlusive disease: recent progress and current challenges. <i>Respiratory Medicine</i> , 2010 , 104 Suppl 1, S23-32	4.6	78
23	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. <i>Circulation</i> , 2010 , 122, 156-63	16.7	1035
22	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. <i>Aids</i> , 2010 , 24, 67-75	3.5	118
21	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. <i>Chest</i> , 2010 , 137, 1297-303	5.3	38
20	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009 , 26, 813-25	4.1	75
19	Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 948-55	3.8	88
18	Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2127-34	15.1	409

17	Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2008 , 2, 249-65	4.9	30
16	Clinical outcomes of pulmonary arterial hypertension in carriers of BMP2 mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1377-83	10.2	225
15	Portopulmonary hypertension: survival and prognostic factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 637-43	10.2	175
14	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. <i>Medicine (United States)</i> , 2008 , 87, 220-233	1.8	229
13	Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. <i>Arthritis and Rheumatism</i> , 2008 , 58, 521-31		261
12	Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. <i>Medicine (United States)</i> , 2007 , 86, 299-315	1.8	118
11	Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2007 , 49, 1-5	3.1	67
10	Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2007 , 26, 357-62	5.8	105
9	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2006 , 27, 589-95	9.5	224
8	Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. <i>Gastroenterology</i> , 2006 , 130, 120-6	13.3	240
7	Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2546-52	15.1	393
6	Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. <i>Chest</i> , 2006 , 130, 182-9	5.3	254
5	Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. <i>Chest</i> , 2005 , 128, 622S	5.3	19
4	Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. <i>Anesthesiology</i> , 2005 , 102, 1133-7; discussion 5A-6A	4.3	234
3	Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. <i>Circulation</i> , 2005 , 111, 3105-11	16.7	815
2	An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. <i>Hemoglobin</i> , 2003 , 27, 139-47 ^{0.6}		53
1	Right heart failure ³²⁻⁴⁷		